Objective: This study compared the effects of duloxetine, 60 mg/day, versus placebo on
cognition, depression, and pain in elderly patients with recurrent major depressive disorder …

Objective To compare the efficacy of duloxetine with placebo on depression in elderly
patients with major depressive disorder. Design Multicenter, 24-week (12-week short-term …

Background: Despite treatment advances, major depressive disorder (MDD) is still a
significant cause of morbidity and mortality. Current therapies frequently fall short of …

Background: Depression is underdiagnosed in the primary care setting. Physical symptoms
such as aches, pains, and gastrointestinal disturbance are frequently associated with major …

Objective: To evaluate duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine,
on improvement of emotional and painful physical symptoms. Design: Randomized, double …

BACKGROUND:: Duloxetine hydrochloride has recently been approved by the US Food and
Drug Administration for the treatment of major depressive disorder (MDD). Duloxetine is a …

Background: Depression is a chronic recurring disorder and guidelines recommend long-
term therapy. This clinical trial evaluated the long-term (1 year) safety and efficacy of …

Objective To examine the safety and tolerability of the antidepressant duloxetine across
multiple studies for major depressive disorder (MDD). Method Safety data were integrated …

Background: Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and
norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment …

Existing therapies for major depressive disorder (MDD) have either limited efficacy and/or
poor tolerability. The present study examined the effects of duloxetine, a potent and …